The incidence of malignancy in the residual rectum of IBD patients after colectomy: a systematic review and meta-analysis

I Georganta, S McIntosh, D Boldovjakova, C N Parnaby, A J M Watson, G Ramsay* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
2 Downloads (Pure)

Abstract

BACKGROUND: Patients with inflammatory bowel disease (IBD) who have had a total colectomy remain with their rectum in situ, and are therefore at risk of rectal carcinoma. It is not clear how high the incidence of rectal cancer is in this cohort. The primary objective of this meta-analysis was to estimate the incidence of rectal cancer in patients with ulcerative colitis or Crohn's disease who have undergone colectomy but have a residual rectum, and to identify the risk factors for its development. In doing so, we explore the current recommendations for screening processes for these patients.

METHODS: A systematic review of the literature was performed. Five databases (Medline, Embase, Pubmed, Cochrane Library and Scopus) were searched from inception to 29 October 2021, to identify studies adhering to the population, intervention, control and outcomes (PICO) criteria. The included studies were critically appraised, and the relevant data was extracted. Cancer incidence was estimated from the reported information. Risk stratification was analysed using RevMan. A narrative approach was undertaken for the exploration of the existing screening guidelines.

RESULTS: Data from 23 of the 24 identified studies was suitable for analysis. The pooled incidence of rectal carcinoma was calculated to be 1.3%. Subgroup analysis showed an incidence of 0.7% and 3.2% for patients with a de-functioned rectal stump and ileorectal anastomosis, respectively. Patients with a history of a colorectal carcinoma were more likely to have a subsequent diagnosis of rectal carcinoma (RR 7.2, 95% CI 2.4-21.1). Patients with previous colorectal dysplasia were also at higher risk (RR 5.1, 95% CI 3.1-8.2). No universal standardised guidance regarding screening for this cohort could be identified in the available literature.

CONCLUSIONS: The overall risk of malignancy was estimated to be 1.3%, which is lower than previously reported. There is a need for clear and standardised screening guidance for this group of patients.

Original languageEnglish
Pages (from-to)699-712
Number of pages14
JournalTechniques in coloproctology
Volume27
Issue number9
Early online date12 Mar 2023
DOIs
Publication statusPublished - Sept 2023

Bibliographical note

Acknowledgements
The authors would like to kindly thank Mr. Rob Polson for his valuable assistance with the search strategy.
Funding
There was no funding provided for this study.

Data Availability Statement

The data that support the findings of this study are openly available in the reference list provided below.

Keywords

  • Infammatory bowel disease
  • Rectal stump
  • Ileal–rectal anastomosis
  • Rectal malignancy

Fingerprint

Dive into the research topics of 'The incidence of malignancy in the residual rectum of IBD patients after colectomy: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this